awmsg logo



mitotane (Lysodren®)


Reference No. 1442

Publication date:
19/06/2012


Appraisal information

mitotane (Lysodren®) 500 mg tablet


Company: HRA Pharma UK & Ireland Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 19/06/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, mitotane (Lysodren®) cannot be endorsed for use within NHS Wales for the treatment of symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma.
Statement of Advice (SOA)
Download